Susmed (TSE:4263) GF Value Rank: 8 (As of Aug. 01, 2026) — 300% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
69 GF Score
Price 円714.00
GF Value 円849.08
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Susmed GF Value Rank?

Susmed TSE:4263 +6.09% 69 GF Value Rank is 8 as of Aug. 01, 2026, which is 300% above its 10-year median of 2.00. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円849.08 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Susmed has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


TSE:4263 vs VEEV, BTSG, HQY: GF Value Rank Comparison

For the Health Information Services subindustry, Susmed's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Susmed GF Value Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Susmed's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Susmed's GF Value Rank falls into.


TSE:4263
69GF Score
Susmed Inc TSE:4263
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Susmed (TSE:4263) has a GF Value Rank of 8 as of Aug. 01, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Susmed and its competitors. This is 300% above median its historical median of 2.00. Over the past decade, Susmed's GF Value Rank has ranged from 2.00 to 10.00.
Is Susmed's GF Value Rank too high?
Susmed's current GF Value Rank of 8 is 300% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's GF Value Rank compare to VEEV and BTSG?
Susmed's GF Value Rank of 8 can be compared against companies in the Healthcare Providers & Services industry. Historically, Susmed's own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Healthcare Providers & Services company?
A good GF Value Rank depends on the Healthcare Providers & Services industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Susmed and its competitors. Susmed's current GF Value Rank is 8, which is 300% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円849.08, compared to a current price of 円714.00 — trading 15.9% below its estimated fair value. The current GF Value Rank is 8, which is 300% above median its 10-year median of 2.00. Susmed's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Susmed (TSE:4263), the current GF Value Rank is 8 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円714.00 is trading 15.9% below its estimated GF Value™ of 円849.08. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • GF Value Rank: 8 (300% above median its 10-year median of 2.00)
  • GF Value™: 円849.08 vs. price of 円714.00 (15.9% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score

Get the complete analysis for TSE:4263

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円714.00
Price
円849.08
GF Value